ACTRN12615000197538
Withdrawn
未知
A randomised controlled trial of breast cancer patients treated with chemotherapy in a hospital day unit or at home; an analysis of cost and patient reported outcomes
A/Prof Suzanne Robinson0 sites130 target enrollmentMarch 2, 2015
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Breast cancer
- Sponsor
- A/Prof Suzanne Robinson
- Enrollment
- 130
- Status
- Withdrawn
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The inclusion criteria for study participants are: scheduled to receive chemotherapy for breast cancer and suitable for day\-case administration; expect to receive at least four cycles of chemotherapy; are aged 18 years or older; WHO performance status of 0,1 or 2, and are able to provide written informed consent. Patients have received two doses of chemotherapy in the hospital\-based chemotherapy unit without adverse events prior to enrolment in the study.
Exclusion Criteria
- •Participants who are \<18 years old; Those who are unable to give informed consent for any reason; Chemotherapy regimens requiring more than 2 hours administration time; Concurrent uncontrolled medical illness likely to interfere with compliance and a serious adverse event (defined as CTCAE v4 GIII/IV adverse event) during administration of cycles 1 or 2; Patients who suffer either anaphylactic or severe hypersensitivity reaction in the first two cycles of treatment in the hospital day unit; only female patients will be recruited.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Randomised controlled trial in breast cancer genetic counselingGenetic counseling, web-based tailored info, communication, breast cancerCancerBreast cancer genetic counselingISRCTN82643064etherlands Institute for Health Services Research (NIVEL) (The Netherlands)200
Active, not recruiting
Phase 1
Pivotal study in breast cancer patients investigating efficacy and safety of LA-EP2006 and Neulasta®Breast CancerTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-002039-28-ESSandoz GmbH308
Completed
Phase 3
A study to evaluate the Efficacy and Safety of LA-EP2006 and Neulasta® in patients with breast cancer.CTRI/2012/10/003065Sandoz GmbH302
Recruiting
Not Applicable
Verification of the effectiveness of breast cancer education for healthy peoplehealthy peopleJPRN-UMIN000046287Tokyo Medical and Dental Univ.300
Terminated
Not Applicable
Improving access to psychological services for people with cancer: A randomised controlled trial of an interactive web-based intervention (CancerCope)ACTRN12613001026718Griffith University490